Organovo has been granted a patent for compounds that act as farnesoid X receptor agonists. These compounds can be used in the treatment of gastrointestinal diseases or conditions in mammals. The patent also covers methods of making the compounds, pharmaceutical compositions containing them, and their use in treating conditions associated with farnesoid X receptor activity. GlobalData’s report on Organovo gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Organovo, 3D Bioprinting was a key innovation area identified from patents. Organovo's grant share as of September 2023 was 36%. Grant share is based on the ratio of number of grants to total number of patents.
A recently granted patent (Publication Number: US11773094B2) discloses a method for treating gastrointestinal diseases or conditions in mammals. The method involves administering a compound of Formula (I') or a pharmaceutically acceptable salt thereof. The compound may also have the structure of Formula (Ia') or a pharmaceutically acceptable salt thereof.
The patent claims specify various aspects of the method. For instance, claim 3 states that the compound may have a 4-, 5-, or 6-membered heterocycloalkyl ring, which may contain an additional heteroatom selected from O, S, and N. The ring may also be substituted with groups such as —OH, —N(C1-C4alkyl)2, C1-C6alkyl, C1-C6alkoxy, —S(-O)2(C1-C4alkyl), —C1-C4alkyl-S(-O)2(C1-C4alkyl), —C1-C6alkyl-OR17, and —O—C1-C6alkyl-OR17. Claim 4 specifies that R8, a substituent in the compound, may be C4-C8alkyl.
Furthermore, claim 5 describes that R4 and R5 in the compound can form a bridge that is —CH2CH2—. Claim 6 adds that R12 and R13 can form a 4-membered or 5-membered heterocycloalkyl ring, which may contain an additional heteroatom selected from O, S, and N. This ring can also be substituted with groups such as —OH, —N(C1-C4alkyl)2, C1-C6alkyl, and C1-C6alkoxy. Claims 7 and 8 specify that each X4 and X3 in the compound can be CH, respectively.
The patent also covers the treatment of specific gastrointestinal diseases or conditions. Claim 15 mentions various conditions, including necrotizing enterocolitis, gastritis, ulcerative colitis, Crohn's disease, inflammatory bowel disease, irritable bowel syndrome, and more. Claim 16 further specifies that the gastrointestinal disease or condition can be inflammatory bowel disease or irritable bowel syndrome.
In addition, claim 14 specifically addresses the treatment of primary biliary cirrhosis (PBC), primary sclerosing cholangitis (PSC), nonalcoholic steatohepatitis (NASH), nonalcoholic fatty liver disease (NAFLD), intrahepatic cholestasis, Ala ille syndrome, or biliary atresia.
Overall, the granted patent provides a method for treating gastrointestinal diseases or conditions in mammals using specific compounds. The method covers a wide range of diseases and conditions, including inflammatory bowel disease and irritable bowel syndrome. This patent may have implications for the development of new treatments in the field of gastroenterology.
To know more about GlobalData’s detailed insights on Organovo, buy the report here.
See Also:
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
